Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO

CERo Therapeutics

CERO THERAPEUTICS HOLDINGS, INC.

CERo Therapeutics clinical programs — 47 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
Status
Public
HQ
201 Haskins Way, 230, South San Francisco, California 94080, US
Employees
17
Programs
47
Drugs
84
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

CERo Therapeutics projects

47 ClinicalTrials.gov programs sponsored by CERo Therapeutics.

CERo Therapeutics has 47 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

47 programs

Clinical programs

  1. BRADI ICO-2023-15

    CERO THERAPEUTICS HOLDINGS, INC.

    Brain metastases of cancer > brain radionecrosis

    phase 3 small molecule active

    1 trial

  2. ENGIC 06 FRUQUITAS

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. FUNGEMAX

    CERO THERAPEUTICS HOLDINGS, INC.

    Metastatic pancreatic cancer

    phase 3 small molecule active

    1 trial

  4. GCO-003 TARLANEC

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  5. IFCT-1701

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. IFCT-1805

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. IFCT-2103

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

  9. NIVOLUMAB for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. PRODIGE 118-PEHRICCA

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  11. PRODIGE 49 -OSCAR

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  12. PRODIGE 51 - GASTFOX

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  13. PRODIGE85-KANALRAD

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  14. ZOSTER ICO-N-2018-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy

    phase 3 small molecule active

    1 trial

  15. Cyramza /ml concentrate for stomach cancer stage IV with me…

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  16. Dopacis 90 MBq/ml oplossing voor injectie

    CERO THERAPEUTICS HOLDINGS, INC.

    patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI

    phase 2 small molecule active

    1 trial

  17. ENGIC 01-COLOSOTO

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  18. FFCD 1605 OPTIPRIME

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. FFCD 1709 - SIRTCI

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  20. FFCD 2006 NEORAF

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  21. FFCD1703

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  22. FRUZAQLA hard capsules for métastatique colorectal cancer

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

  23. Fianlimab for Pleural mesothelioma

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  24. ICO-2020-01 REPAIR

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  25. ICO-2023-10

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  26. ICO-2023-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  27. ICO-N-2013-03

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  28. IFCT-1904

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. IFCT-2003

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  30. IFCT-2101

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  31. IFCT-2401 SPORADIC

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. IFCT-2502

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  33. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  34. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  35. PRODIGE 104 A

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. PRODIGE 111

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  37. PRODIGE 34 - ADAGE

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  38. Prodige 54 SAMCO

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  39. TEP-64Cu-ATSM-Rectum

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  40. ivonescimab

    CERO THERAPEUTICS HOLDINGS, INC.

    pleural mesothelioma

    phase 2 small molecule active

    1 trial

  41. CER-1236

    CERO THERAPEUTICS HOLDINGS, INC.

    AML

    phase 1 small molecule active

    1 trial

  42. ICO-2023-16

    CERO THERAPEUTICS HOLDINGS, INC.

    cell lung carcinoma

    phase 1 other active

    1 trial

  43. ICO-2023-25 OPTIMISE

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic prostate cancer

    phase 1 other active

    1 trial

  44. PERSEVERANCE EU

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  45. [68Ga]Ga-PentixaFor

    CERO THERAPEUTICS HOLDINGS, INC.

    triple-negative breast cancer

    phase 1 small molecule active

    1 trial

  46. EC-120888

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)

    approved small molecule active

    1 trial

  47. IDEA

    CERO THERAPEUTICS HOLDINGS, INC.

    Ulcerative Colitis

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does CERo Therapeutics have?

47 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.